Selected article for: "cardiac function and SARS cov"

Author: Bottari, Gabriella; Confalone, Valerio; Cotugno, Nicola; Guzzo, Isabella; Perdichizzi, Salvatore; Manno, Emma C.; Stoppa, Francesca; Cecchetti, Corrado
Title: Efficacy of CytoSorb in a Pediatric Case of Severe Multisystem Infammatory Syndrome (MIS-C): A Clinical Case Report
  • Cord-id: hqbfe2l9
  • Document date: 2021_6_11
  • ID: hqbfe2l9
    Snippet: Background: Multisystem inflammatory syndrome in children (MIS-C) has emerged during the COVID-19 pandemic as a new SARS-CoV-2-related entity, potentially responsible for a life-threatening clinical condition associated with myocardial dysfunction and refractory shock. Case: We describe for the first time in a 14-year-old girl with severe MIS-C the potential benefit of an adjuvant therapy based on CytoSorb hemoperfusion and continuous renal replacement therapy with immunomodulatory drugs. Conclu
    Document: Background: Multisystem inflammatory syndrome in children (MIS-C) has emerged during the COVID-19 pandemic as a new SARS-CoV-2-related entity, potentially responsible for a life-threatening clinical condition associated with myocardial dysfunction and refractory shock. Case: We describe for the first time in a 14-year-old girl with severe MIS-C the potential benefit of an adjuvant therapy based on CytoSorb hemoperfusion and continuous renal replacement therapy with immunomodulatory drugs. Conclusions: We show in our case that, from the start of extracorporeal blood purification, there was a rapid and progressive restoration in cardiac function and hemodynamic parameters in association with a reduction in the most important inflammatory biomarkers (interleukin 6, interleukin 10, C-reactive protein, ferritin, and D-dimers). Additionally, for the first time, we were able to show with analysis of the sublingual microcirculation a delayed improvement in most of the important microcirculation parameters in this clinical case of MIS-C.

    Search related documents:
    Co phrase search for related documents
    • adjuvant therapy and low molecular weight: 1, 2, 3, 4
    • adjuvant therapy and low molecular weight heparin: 1, 2, 3, 4
    • adjuvant therapy and lymphocyte count: 1, 2, 3
    • lmwh low molecular weight heparin and low molecular weight: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and low molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh low molecular weight heparin and lymphocyte count: 1
    • long term sequelae and low molecular weight: 1
    • long term sequelae and low molecular weight heparin: 1
    • long term sequelae and lymphocyte count: 1
    • low molecular weight and lymphocyte count: 1, 2, 3, 4, 5
    • low molecular weight heparin and lymphocyte count: 1, 2, 3, 4